Últimas noticias sobre WAVE Life Sciences (NASDAQ:WVE) Bolsa

WAVE Life Sciences

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences Ltd

WIIM

Wave Life Sciences shares are trading lower after the company announced the pricing of its upsized $200 million offering of 23.1 million shares at $8 per share.

The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wve#NASDAQ">WVE</a>), whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
However, rate cuts are not the only reason for excitement around the company. The average of recent Wall Street analyst price targets signals an 85% upside potential in the stock. I&#39;ll analyze the progress Wave Life Sciences has made in its treatment, its financial situation, and what to watch for next.
<h2>Wave May Have an &quot;Industry-Leading&quot; DMD Treatment</h2>
Wave currently has four drugs in development, but I&#39;ll focus on WVE-N531. This drug aims to treat Duchenne Muscular Dystrophy (DMD), a condition that mostly affects young boys. The drug is currently in Phase 2 Food and Drug Administration (FDA) trials.
DMD is characterized by low levels of dystrophin production. One of the main ways to increase dystrophin production is through &quot;exon skipping.&quot; These drugs help the body skip over malfunctioning parts of the genetic code (exons) that cause low dystrophin levels. By skipping over these exons, the body should produce more dystrophin. Wave&#39;s drug specifically aims to skip over exon 53.
In the company&#39;s preclinical trials, the drug achieved exon skipping levels of 53%. The firm says this percentage is &quot;industry-leading.&quot; Although the company does not cite how much dystrophin production increased, exon skipping correlates with it. So, it is possible that dystrophin production could be industry-leading as well.
From a business perspective, one issue with this treatment is that the market is very small. Different people are affected by different exons malfunctioning. Since WVE-N531 is being researched specifically to skip exon 53, it is currently only aimed at treating 8% to 10% of DMD patients. In the United States and Europe, that is only around 2,300 people. Still, this could result in significant revenue.
According to the firm, exon-skipping treatments brought in $1 billion industry-wide in 2023. Those affected by exon 53 make up around a quarter of the total when looking at the five largest exon patient groups. So, it&#39;s conceivable that there may be a current market of around $250 million for the drug. The DMD market is expected to continue growing considerably; however, estimates are wide-ranging, from 10% to 39% per year.
<h2>Wave&#39;s Financials Show Positives and Negatives</h2>
Over the past several years, Wave Life Sciences hasn&#39;t been a good investment at all. The stock has provided a cumulative total return of just 5% in three years. As with many small firms in the pharma industry, Wave currently has no approved medications. However, the company has been able to generate some significant revenue.
Wave has generated at least $12 million in revenue in each of the last six quarters. This revenue mainly comes from &quot;collaborations&quot; with large pharmaceutical companies.&nbsp;Takeda (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tak#NYSE">TAK</a>)&nbsp;and&nbsp;GSK (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gsk#NYSE">GSK</a>) have collaborated with Wave. Although Wave isn&#39;t generating&nbsp;much revenue, anything helps when the company is spending $30 million to $40 million a quarter on research and development.
The company currently has $154 million in cash and equivalents on its balance sheet. That may last a little over a year, considering the company has burned through $130 million in cash from operations over the last twelve months. It will need to issue more stock soon, which will dilute shareholders.
<h2>Good News Around WVE-N531 and What to Watch For</h2>
The company&nbsp;recently received good news regarding the drug. The FDA granted the drug the&nbsp;Rare Pediatric Disease Designation. This means that if the drug is approved, the company will receive a Priority Review Voucher (PRV). The PRV allows the company to speed up the review of a future drug by four months. However, PRVs can also be sold to other companies.
Recent data shows that PRVs are now selling for an average of $100 million. Thus, selling the PRV could bring in significant revenue if WVE-N531 is approved. Alternatively, it could use the PRV itself to speed up the review of its own future treatments.
I&#39;ll be watching Waves&#39; upcoming results for WVE-N531, which they plan to release in Q3. The results will include data on changes in dystrophin levels. Seeing the number come in above the 5.7% to 5.9% increase of the already approved treatment Viltepso could add significant validity to the Wave Life Sciences bull case.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/analysts-predict-85-upside-for-wave-life-sciences-after-rate-cut/">Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</a>&quot; first appeared on MarketBeat.

Biotech

Large Cap

News

Price Target

Small Cap

Federal Reserve

Markets

Analyst Ratings

Trading Ideas

General

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.
&nbsp;
Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. All of the securities in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about September 27, 2024, subject to customary closing conditions. 
&nbsp;

Offerings

Reported Earlier, Wave Life Sciences Upsizes Offering To $200M Of 23.1M Shares At $8/Share

Wave Life Sciences shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $15 to $22.

Jones Trading analyst Catherine Novack maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $12 to $16.

Jones Trading Maintains Buy on WAVE Life Sciences, Raises Price Target to $16

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley cut the price target for General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from $47 to $42. Morgan Stanley analyst Adam Jonas downgraded the stock from Equal-Weight to Underweight. General Motors shares rose 0.1% to close at $48.07 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this </a><a href="https://www.benzinga.com/quote/GM/analyst-ratings">stock</a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">.</a></li>
<li>Loop Capital increased the price target for monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from $285 to $310. Loop Capital analyst Mark Schappel maintained a Buy rating. monday.com shares gained 1.3% to close at $281.64 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how </a><a href="https://www.benzinga.com/quote/MNDY/analyst-ratings">other </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analysts view this stock</a>.</li>
<li>Northland Capital Markets raised Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) price target from $7 to $9. Northland Capital Markets analyst Michael Latimore maintained an Outperform rating. Gorilla Technology shares fell 2.7% to close at $4.38 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view </a><a href="https://www.benzinga.com/quote/GRRR/analyst-ratings">this </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">stock</a>.</li>
<li>TD Cowen cut Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) price target from $103 to $95. TD Cowen analyst Cai Rumohr downgraded the stock from Buy to Hold. Textron shares fell 0.2% to close at $86.68 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how </a><a href="https://www.benzinga.com/quote/TXT/analyst-ratings">other </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) price target from $15 to $22. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Wave Life Sciences shares gained 53.4% to close at $8.19 on Tuesday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Baird cut the price target for Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) from $35 to $27. Baird analyst Jonathan Komp maintained a Neutral rating. Foot Locker gained 0.6% to close at $27.48 on Tuesday. <a href="https://www.benzinga.com/quote/FL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) price target from $245 to $310. Needham analyst Ryan MacDonald maintained a Buy rating. Duolingo shares fell 0.2% to close at $269.79 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how </a><a href="https://www.benzinga.com/quote/DUOL/analyst-ratings">other </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analysts view this stock</a>.</li>
<li>Evercore ISI Group cut the price target for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from $254 to $247. Evercore ISI Group analyst Jonathan Chappell downgraded the stock from Outperform to In-Line. Union Pacific shares gained 2% to close at $248.96 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this </a><a href="https://www.benzinga.com/quote/UNP/analyst-ratings">stock</a>.</li>
<li>JMP Securities raised Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) price target from $170 to $210. JMP Securities analyst Aaron Hecht maintained a Market Outperform rating. Lennar shares fell 0.8% to close at $184.23 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how </a><a href="https://www.benzinga.com/quote/LEN/analyst-ratings">other </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analysts view this stock</a>.</li>
<li>Keybanc slashed Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) price target from $145 to $135. Keybanc analyst Alex Markgraff maintained an Overweight rating. Global Payments shares fell 6.5% to close at $103.81 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other </a><a href="https://www.benzinga.com/quote/GPN/analyst-ratings">analysts </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">view this stock</a>.</li>
</ul>
Considering buying GM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25085351/image-203-1024x584.png" alt="" class="wp-image-565428" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25085351/image-203-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25085351/image-203-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25085351/image-203-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25085351/image-203.png 1175w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Pre-Market Outlook

DUOL

GRRR

MNDY

General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday.
Shares of Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/09/41014297/stitch-fix-stock-falls-after-q4-results-heres-why">fourth-quarter EPS results</a>.
Stitch Fix reported quarterly losses of 29 cents per share, which missed the analyst consensus estimate for losses of 19 cents. Quarterly revenue of $319.6 million beat the analyst consensus estimate of $318.5 million and is a 12.4% decrease year-over-year.
Stitch Fix shares dipped 25.6% to $2.79 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) shares dipped 17.9% to $7.75 in pre-market trading. Target Hospitality Announced that its board of directors has decided to disband the special committee, which was formed solely of independent directors.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) declined 7.5% to $19.91 in pre-market trading after gaining 5% on Tuesday.</li>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) shares fell 7.1% to $81.19 in pre-market trading following third-quarter financial results.</li>
<li>Zai Lab Ltd – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares declined 5.2% to $20.45 in pre-market trading.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares fell 4.8% to $17.73 in pre-market trading after surging 17% on Tuesday.</li>
<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares slipped 4.8% to $7.80 in pre-market trading after the company announced a $175 million proposed public offering of ordinary shares and pre-funded warrants.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares declined 4.6% to $10.21 in pre-market trading after jumping 12% on Tuesday.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) shares fell 4% to $32.55 in pre-market trading after gaining 14% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41013033/top-4-industrials-stocks-which-could-rescue-your-portfolio-this-quarter">Top 4 Industrials Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Movers

BILI

SFIX

XPEV

ZLAB

Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

HC Wainwright &amp; Co. analyst Andrew Fein maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $15 to $22.

HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Raises Price Target to $22

Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences. &nbsp;
J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering. Truist Securities and Mizuho are acting as book-runners for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Wave Life Sciences Announces $175M Proposed Public Offering Of Ordinary Shares and Pre-Funded Warrants

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday.
The Dow traded down 0.04% to 42,109.03 while the NASDAQ rose 0.51% to 18,065.98. The S&amp;P 500 also rose, gaining, 0.14% to 5,726.56.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41000017/how-to-earn-500-a-month-from-nvidia-stock">How To Earn $500 A Month From Nvidia Stock</a>
Leading and Lagging Sectors Materials shares jumped by 1.2% on Tuesday.
In trading on Tuesday, financials shares fell by 1.1%.
Top Headline
Thor Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) reported better-than-exp earnings for its fourth quarter on Tuesday.
The company reported fourth-quarter earnings per share of $1.68, beating the street view of $1.43. Quarterly sales of $2.534 billion (down 7.4%) outpaced the analyst consensus of $2.471 billion.
Thor Industries said it anticipates fiscal year 2025 sales between $9.0 billion and $9.8 billion, compared to the $10.49 billion estimate, and expects EPS to range from $4.00 to $5.00, below the estimated $6.65.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Maison Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) shares shot up 115% to $1.5792 after the company reported a year-over-year increase in first-quarter sales results.</li>
<li>Shares of Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) got a boost, surging 76% to $0.3356 after the company announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense&#8217;s military and veterans adaptive platform clinical trial for PTSD.</li>
<li>Wave Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares were also up, gaining 53% to $8.18 after the company announced interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy.</li>
</ul>
Equities Trading DOWN
<ul>
<li>BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares dropped 56% to $1.2399 after the company announced it raised $3 million through a secondary offering of 1.96 million shares at $1.53 per share.</li>
<li>Shares of Laser Photonics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) were down 16% to $15.75. Laser Photonics appointed Robert Hoffman as its new Outside Sales Director.</li>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) was down, falling 18% to $92.51 after Susquehanna lowered its price target on the stock from $92 to $90.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $71.31 while gold traded up 0.9% at $2,676.60.
Silver traded up 4.2% to $32.385 on Tuesday, while copper rose 3.4% to $4.4940.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 rose 0.65%, Germany's DAX gained 0.80% and France's CAC 40 gained 1.28%. Spain's IBEX 35 Index rose 0.33%, while London's FTSE 100 rose 0.28%.
The Ifo Business Climate indicator for Germany fell to 85.4 in September versus 86.6 in the previous month.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.57%, Hong Kong's Hang Seng Index jumping 4.13%, China's Shanghai Composite Index gaining 4.15% and India's BSE Sensex gaining 0.02%.
The au Jibun Bank Flash Japan composite PMI declined to 52.5 in September compared to a final reading of 52.9 in August.
Economics
<ul>
<li>The S&amp;P CoreLogic Case-Shiller home price index in increased by 5.9% year-over-year in July compared to a 6.5% rise in the previous month.</li>
<li>The FHFA house prices index rose 0.1% in July, compared to market estimates of a 0.2% increase. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40999381/top-4-industrials-stocks-which-could-rescue-your-portfolio-this-quarter">Top 4 Industrials Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

BIVI

LASE

Merrill Lynch & Strategic Return Notes for Select 10 Index

SEEL

Crude Oil Gains Over 1%; BioVie Shares Plunge

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday.
The Dow traded up 0.07% to 42,156.22 while the NASDAQ rose 0.56% to 18,075.07. The S&amp;P 500 also rose, gaining, 0.21% to 5,730.61.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41000017/how-to-earn-500-a-month-from-nvidia-stock">How To Earn $500 A Month From Nvidia Stock</a>
Leading and Lagging Sectors Materials shares jumped by 1.2% on Tuesday.
In trading on Tuesday, financials shares fell by 0.6%.
Top Headline
Thor Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) reported better-than-exp earnings for its fourth quarter on Tuesday.
The company reported fourth-quarter earnings per share of $1.68, beating the street view of $1.43. Quarterly sales of $2.534 billion (down 7.4%) outpaced the analyst consensus of $2.471 billion.
Thor Industries said it anticipates fiscal year 2025 sales between $9.0 billion and $9.8 billion, compared to the $10.49 billion estimate, and expects EPS to range from $4.00 to $5.00, below the estimated $6.65.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Maison Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) shares shot up 106% to $1.5199 after the company reported a year-over-year increase in first-quarter sales results.</li>
<li>Shares of Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) got a boost, surging 170% to $0.5130 after the company announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense&#8217;s military and veterans adaptive platform clinical trial for PTSD.</li>
<li>Wave Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares were also up, gaining 37% to $7.33 after the company announced interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy.</li>
</ul>
Equities Trading DOWN
<ul>
<li>BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares dropped 53% to $1.31 after the company announced it raised $3 million through a secondary offering of 1.96 million shares at $1.53 per share.</li>
<li>Shares of Laser Photonics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) were down 14% to $16.10. Laser Photonics appointed Robert Hoffman as its new Outside Sales Director.</li>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) was down, falling 17% to $93.96 after Susquehanna lowered its price target on the stock from $92 to $90.</li>
</ul>
Commodities In commodity news, oil traded up 2% to $71.80 while gold traded up 0.3% at $2,660.00.
Silver traded up 0.9% to $31.355 on Tuesday, while copper rose 3% to $4.4795.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.58%, Germany's DAX gained 0.63% and France's CAC 40 gained 1.31%. Spain's IBEX 35 Index fell 0.01%, while London's FTSE 100 rose 0.16%.
The Ifo Business Climate indicator for Germany fell to 85.4 in September versus 86.6 in the previous month.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.57%, Hong Kong's Hang Seng Index jumping 4.13%, China's Shanghai Composite Index gaining 4.15% and India's BSE Sensex gaining 0.02%.
The au Jibun Bank Flash Japan composite PMI declined to 52.5 in September compared to a final reading of 52.9 in August.
Economics
<ul>
<li>The S&amp;P CoreLogic Case-Shiller home price index in increased by 5.9% year-over-year in July compared to a 6.5% rise in the previous month.</li>
<li>The FHFA house prices index rose 0.1% in July, compared to market estimates of a 0.2% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40999381/top-4-industrials-stocks-which-could-rescue-your-portfolio-this-quarter">Top 4 Industrials Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Intraday Update

Nasdaq Surges 100 Points; Thor Industries Earnings Top Views

On Tuesday, Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40999215/wave-life-sciences-announces-positive-interim-data-from-forward-53-clinical-trial-evaluating-wve-n" rel="noreferrer noopener">to exon 53 skipping</a>.
DMD is&nbsp;a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene. It&#8217;s the most common inherited neuromuscular disease and affects boys more often than girls.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39480161/whats-going-on-with-wave-life-sciences-stock-on-tuesday" rel="noreferrer noopener">What&#8217;s Going On With Wave Life Sciences Stock On Tuesday?</a>
Dystrophin is&nbsp;a protein that helps strengthen and protect muscle fibers.
Eleven boys amenable to exon 53 skipping (age 5-11; 10 ambulatory and one non-ambulatory) are enrolled.
Dystrophin results from a pre-specified analysis of ambulatory (who can walk) boys showed:
<ul>
<li>The mean absolute muscle content-adjusted dystrophin expression was 9.0%, and the mean absolute unadjusted dystrophin expression was 5.5% of normal.</li>
<li>89% of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5%.</li>
</ul>
The mean exon skipping was 57%.
WVE-N531 was detected in myocyte nuclei in all participants and myogenic stem cells in most participants. Myogenic stem cells are the progenitor cells for new myoblasts, which give rise to new myocytes and ultimately aid in skeletal muscle regeneration.
Participants showed multiple indicators of improvement in muscle health.
Significant reductions were observed in serum biomarkers associated with muscle damage.
WVE-N531 was safe and well tolerated. Treatment-related adverse events (four events total in three participants) were mild in intensity.
There were no oligonucleotide class-related safety events.
In the first quarter of 2025, Wave expects to complete the FORWARD-53 trial and receive feedback from regulators on a pathway to accelerated approval.
Price Action: WVE stock is up 47.90% at $7.88 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41004167/ready-for-the-road-ford-opens-orders-for-2025-f-series-super-duty-truck" target="_blank" rel="noreferrer noopener">Ready For The Road &#8211; Ford Opens Orders For 2025 F-Series Super Duty Truck</a>.</li>
</ul>

Health Care

Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug

U.S. stocks were lower, with the Dow Jones index falling around 200 points on Friday.
Shares of Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) rose sharply during Tuesday's session after the company announced interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 for <a href="https://www.benzinga.com/quote/WVE/news">Duchenne muscular dystrophy.</a>
Wave Life Sciences shares surged 37.9% to $7.36 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) gained 23.8% to $74.06 after the company announced that it submitted a counterproposal to charter for the proposed business combination.</li>
<li>Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) gained 15% to $14.64. Shares of US-listed Chinese companies traded higher after China Central Bank announced a new stimulus package.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) surged 12.7% to $17.94.</li>
<li>Tencent Music Entertainment Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TME#NASDAQ">TME</a>) gained 12.2% to $11.43. Shares of US-listed Chinese companies traded higher after China Central Bank announced a new stimulus package.</li>
<li>Dada Nexus Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>) shares jumped 11.9% to $1.41. Shares of US-listed Chinese companies traded higher after China Central Bank announced a new stimulus package.</li>
<li>Ramaco Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) surged 10% to $11.15.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) gained 10.7% to $8.21.</li>
<li>iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) jumped 10% to $2.35.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) gained 9.2% to $32.49.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) gained 8.6% to $5.78. Shares of US-listed Chinese companies traded higher after China Central Bank announced a new stimulus package.</li>
<li>SBC Medical Group Holdings Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) rose 8.2% to $6.22. Shares of US-listed Chinese companies traded higher after China Central Bank announced a new stimulus package.</li>
<li>Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) gained 7.5% to $36.80.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) climbed 7.5% to $23.86. Shares of US-listed Chinese companies traded higher after China Central Bank announced a new stimulus package.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) gained 7% to $21.94.</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) shares rose 5.7% to $44.53.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 2.5% to $256.20. The catalyst that is potentially offering support on Tuesday is data out of China that showed that insured registered for Tesla vehicles remained healthy for the recent reporting week.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41002493/top-4-health-care-stocks-that-may-keep-you-up-at-night">Top 4 Health Care Stocks That May Keep You Up At Night</a></li>
</ul>

DADA

LBRDA

METC

TSLA

Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday

Wave Life Sciences shares are trading higher after the company announced interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy.

Wave Life Sciences Announced Interim Data From Ongoing Phase 2 FORWARD-53 study of WVE-N531 For Duchenne Muscular Dystrophy Who Are Amenable To Exon 53 Skipping, Showing Substantial Dystrophin Expression And That It Was Safe And Well Tolerated

Wave Life Sciences shares are trading higher after B. Riley Securities initiated coverage on the stock with a Buy rating and announced a price target of $11.

B. Riley Securities analyst Madison El-Saadi initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $11.

Initiation

B. Riley Securities Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $11

Wave Life Sciences shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $10 price target.

JP Morgan initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight rating and announces Price Target of $10.

JP Morgan Initiates Coverage On WAVE Life Sciences with Overweight Rating, Announces Price Target of $10

William Blair initiated coverage on Korro Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>), a private RNA editing company that went public via a reverse merger with&nbsp;Frequency Therapeutics Inc. in an all-stock&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33229914/why-are-frequency-therapeutics-shares-surging-today" rel="noreferrer noopener">merger transaction</a>.&nbsp;
The company&#8217;s proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform harnesses the body&#8217;s natural base editing system – specifically ADAR (Adenosine&nbsp;Deaminase&nbsp;Acting on&nbsp;RNA) – to make targeted edits to a single RNA base.
William Blair notes that ADAR editing permits chronic dosing and titratability of a genetic editing medicine without the risk of permanent off-target effects or potential issues with over- or underexpression of target genes.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36075434/why-newly-listed-korro-bio-shares-are-gaining-today" rel="noreferrer noopener">Why Newly Listed Korro Bio Shares Are Gaining Today?</a>
William Blair emphasizes that Wave Life Sciences Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is set to release the first clinical data for an ADAR-recruiting therapy in 2024. The analyst initiates <a target="_blank" href="https://www.benzinga.com/quote/KRRO/analyst-ratings" rel="noreferrer noopener">with an Outperform rating</a>.
The data from the Phase 1b/2a RestorAATion-2 trial of WVE-006 for severe Alpha-1 antitrypsin deficiency (A1ATD) will be crucial in determining whether the ADAR-mediated RNA editing mechanism is consistent across species—a key concern for investors due to differences in genetic homology.
Korro&#8217;s lead asset, KRRO-110, is a lipid nanoparticle (LNP)- encapsulated oligonucleotide designed to correct the E342K PiZ mutation in SERPINA1, which can lead to severe forms of alpha-1 antitrypsin deficiency (A1ATD).
The asset is expected to enter a Phase 1/2 trial in adult A1ATD patients in the second half of 2024, with interim proof-of-concept clinical data in 2025 and trial completion in 2026.
&#8220;We believe Korro&#8217;s preclinical data package, particularly in the NSG PiZ mouse model, is best-in-class for the ADAR field,&#8221; William Blair analyst writes.
&#8220;We also believe that Wave&#8217;s WVE-006 (GalNAc-conjugated ADAR-recruiting ASO) and Beam Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) BEAM-302 (base editing approach) clinical programs validate Korro&#8217;s approach but still leave clear room for differentiation on efficacy or specificity/safety,&#8221; the analyst adds.
Price Action: KRRO stock is up 8.64% at $39.50 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40373358/acelyrin-cuts-workforce-deprioritizes-former-lead-drug-izokibep" target="_blank" rel="noreferrer noopener">Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep</a>.</li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference</a> on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
Image via Shutterstock

BEAM

KRRO

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating

Wave Life Sciences gains as B. Riley issues buy on RNS editing tech

Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and keeping the price target at $11.00. ...

Buy Rating on Wave Life Sciences: Undervalued DMD Program and Promising Data Offer Investment Upside

The latest update is out from Wave Life Sciences ( ($WVE) ). Wave Life Sciences Ltd. has reported encouraging interim results from their Phase 2 FO...

Wave Life Sciences Reports Promising Duchenne Therapy Trial Results

Wave Life Sciences gains on data for Duchenne therapy

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his Buy ...

Wave Life Sciences' WVE-N531 Shows Best-in-Class Potential in DMD Treatment, Justifying a Buy Rating

Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet

Wave Life Sciences proposes secondary offering of ordinary shares, pre-funded warrants

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Wave Life Sciences (WVE – Research Report). The company's sha...

Wave Life Sciences (WVE) Gets a Buy from Truist Financial

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed has given his Buy rati...

Wave Life Sciences' Strong Clinical Data and Market Potential Merit Buy Rating

Wave Life Sciences prices $200M stock offering

SRPT

Press Releases

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Comments

WAVE Life Sciences

Noticias

Últimas noticias sobre WAVE Life Sciences (NASDAQ:WVE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL